femoral neck fracture
Conditions
Interventions
Oral group. :1. Oral group: 2 g TXA was orally administered 2 hours before surgery.
Intravenous group:1g TXA was Intravenously administered before incision.
Control group:receive no special intervention related to TXA, usual hemostatic methods including electrocoagulation, anesthetic-controlled hypotension during operation and compression dressing of woun
Sponsors
Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, No. 87 Ding Jia Qiao, Nanjing 210009, Jiangsu Province, China.
Eligibility
Sex/Gender
All
Age
65 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.patients aged =65 years and =85 years old at the time of admission; 2. diagnosed as displaced femoral neck fracture (Garden type III or IV), and the time from the fracture to operation was less than 2 weeks; 3. agree to receive hip arthroplasty surgery; 4. agrees to participate the trial and signed the Informed consent
Exclusion criteria
Exclusion criteria: 1. Recieving anticoagulants (vitamin K antagonists, thrombin inhibitors, antiplatelet drugs, factor II and X inhibitors) or thrombin at the time of admission, ; 2.Combined with other fractures that require surgery; 3. Allergy to TXA; 4. Had history of DVT or PE; 5. Combined with liver dysfunction: alanine aminotransferase (ALT)>40 U/L, aspartate aminotransferase (AST)>40 U/L, or PTA171umol/L; 6. Combined with renal insufficiency: serum urea (BUN)>7.1 µ Mol/L; Blood creatinine (SCr)>110umol/L or glomerular filtration rate below 90ml/min; 7. Combined with active coronary artery disease (past 12 months); 8. Medical history of CVA in the past 12 months; 9. Undergoing drug eluting stent implantation surgery; 10.Combined with leukemia or active cancer; 11. Patients in a hypercoagulable state with serum prothrombin time (PT)<9s and partially activated prothrombin time (APTT)<20s upon admission; 12. Concomitant arrhythmia; 13. Refuse to participate in the experiment.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| perioperative hidden blood loss;intraoperative blood loss;postoperative blood loss;postoperative changes in HB levels;length of hospital stay;Adverse events such as wound infection and hematoma;Related thromboembolic events and death were; | — |
Primary
| Measure | Time frame |
|---|---|
| Blood Transfusion Rate ;total blood loss; | — |
Countries
China
Contacts
Public ContactYunfeng Rui
Department of Orthopaedics, Zhongda Hospital, School of Medicine, Southeast University, No. 87 Ding Jia Qiao, Nanjing 210009, Jiangsu Province, China.
Outcome results
None listed